SEC Form 4 · accession 0001193125-26-391985
NewAmsterdam Pharma Co N.V. · NAMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael H. Davidson
Officer — Chief Executive Officer · Director
Period of report
Sep 14, 2026
Accepted (ET)
Sep 15, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001936258
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Sep 14, 2026 | P | 10,000 | $22.65 | A | 792,923 | D | |
| Ordinary SharesF3 | holding | — | — | — | 285,715 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
- F2Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person. Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person.
- F3These Ordinary Shares are held by the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT"). The Reporting Person is the sole annuitant and trustee of the GRAT.